Skip to main navigation

Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb^®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
- News
- Publications
Careers
Corporate
Investors
Main navigation
Events
Presentations

Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

Science in the service of medicine

About
Pipeline
Clinical Trials
- Patients
- Physicians & Researchers

News & Publications
- News
- Publications
Investors
Main navigation
Events
Presentations
Careers
Contact Us
ActivMAb ^®

News Releases

News Releases

Investors

Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter

News Releases

Keyword Search

Year

11/18/24

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

11/07/24

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

11/05/24

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

10/31/24

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

10/24/24

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

09/18/24

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

08/14/24

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

07/31/24

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

07/17/24

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

06/06/24

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

05/15/24

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

04/02/24

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

03/27/24

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

02/21/24

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

02/15/24

Vaccinex, Inc. Announces Reverse Stock Split

02/07/24

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

About
Pipeline
Clinical Trials

News
Careers
Contact

Vaccinex Inc.
1895 Mount Hope Avenue, Rochester, NY 14620
P: 585-271-2700
F: 585-271-2765
info@vaccinex.com

© 2024 Vaccinex. All rights reserved
Privacy Policy
Site by Minerva